DexCom (DXCM) vs West Pharmaceutical Services (WST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
West Pharmaceutical Services (WST) has outperformed DexCom (DXCM) over the past year, gaining 37.8% versus a gain of 27.7%. Over five years, WST leads with a -9.5% price change compared with -38.1% for DXCM. DexCom is the larger company by market cap ($31.85 billion vs $25.57 billion), about 1.2 times the size.
On valuation, DexCom trades at a lower forward P/E (27.0x vs 36.3x for West Pharmaceutical Services). West Pharmaceutical Services pays a dividend yielding 0.24%, while DexCom does not currently pay one. DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 16.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DXCM | WST |
|---|---|---|
| Share price | $84.41 | $363.27 |
| Market cap | $31.85B | $25.57B |
| 1-day change | +0.13% | -0.88% |
| YTD return | +27.02% | +33.20% |
| 1-year return | +27.67% | +37.79% |
| 5-year return | -38.07% | -9.47% |
| P/E ratio (TTM) | 33.50 | 46.51 |
| Forward P/E | 26.99 | 36.35 |
| EPS (TTM) | $2.52 | $7.81 |
| Dividend yield | 0.00% | 0.24% |
| Annual dividend | $0.00 | $0.87 |
| Revenue (latest FY) | $4.66B | $3.07B |
| Revenue growth (YoY) | +15.60% | +6.25% |
| Net income (latest FY) | $836.30M | $493.70M |
| Gross margin | 60.10% | 35.91% |
| Operating margin | 19.56% | 19.03% |
| Net margin | 17.94% | 16.06% |
| 52-week high | $92.59 | $386.00 |
| 52-week low | $54.11 | $223.83 |
| Distance from 52-week high | -8.83% | -5.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +14.00% | +13.14% |
| Average volume | 4.44M | 626.98K |
| Shares outstanding | 377.36M | 70.38M |
| Employees | 11,000 | 10,800 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WST has outperformed DXCM by 10.1 percentage points over the past year.
- West Pharmaceutical Services trades at a higher earnings multiple (46.5x vs 33.5x trailing P/E).
- DexCom grew revenue faster in its latest fiscal year (+15.60% vs +6.25%).
About DexCom
DXCM stock →DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Health Care · Medical/Dental Instruments · 11,000 employees
About West Pharmaceutical Services
WST stock →West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 10,800 employees
DXCM vs WST FAQ
Which is bigger, DexCom or West Pharmaceutical Services?
DexCom (DXCM) is larger, with a market capitalization of $31.85B compared with $25.57B for West Pharmaceutical Services (WST).
Which stock has performed better over the past year, DXCM or WST?
WST returned +37.79% over the past 12 months, compared with +27.67% for DXCM (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, DXCM or WST?
DXCM has the lower trailing P/E at 33.5, versus 46.5 for WST. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, DexCom or West Pharmaceutical Services?
West Pharmaceutical Services pays a dividend yielding 0.24%, while DexCom does not currently pay a regular dividend.
Are DexCom and West Pharmaceutical Services in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.